Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2010

View Archived Issues

AGN-196923 alleviates neuropathic pain in animal models

GSK-2188931 shows promise in rat model of myocardial infarction

Prodrug delivers fenofibric acid and nitric oxide for cardiovascular disease treatment

Roche identifies new inhibitors of PDE10A

Yondelis obtains marketing authorization for ovarian cancer in Russia

MAP Pharmaceuticals provides update on Levadex clinical development program

Scientists suppress alpha-synuclein expression in primate substantia nigra using siRNA

New gamma-secretase modulators show favorable properties in preclinical evaluation

Primary endpoint met in Renovo's phase I safety studies of Juvista after keloid excision

ImmunoCellular reports long-term disease-free survival data from phase I ICT-107 trial in GBM

GSK and Genmab initiate phase III trial of ofatumumab in indolent B-NHL

Johnson & Johnson to discontinue sale of ceftobiprole for cSSTI in Switzerland

Boehringer Ingelheim presents new C-raf inhibitors

Novel SEH inhibitors disclosed by Takeda Pharmaceutical

Pulmagen Therapeutics claims new MAP kinase p38 alpha inhibitors

Vertex Pharmaceuticals describes new PI3K-gamma inhibitors

Santarus, S2 Therapeutics and VeroScience sign license agreement for Cycloset

GFT-505 shows promise as antidiabetic agent in clinical study

Curaxis presents development plan for Memryte in Alzheimer's disease

FDA requires additional time to review Questcor's H.P. Acthar sNDA

Tragara Pharma begins phase I TG-02 trial in hematological malignancies

Phase III COU-AA-301 trial of abiraterone/prednisone is unblinded due to efficacy

FDA grants Zentylor fast track status for progressive supranuclear palsy

CombinatoRx becomes Zalicus

Novartis receives first approval for Gilenya MS therapy in Russia